XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.21.2

Net Income (Loss) Per Share Attributable to Common Shareholders | 9 Months Ended
--- | ---
Sep. 30, 2021
Earnings Per Share [Abstract] |
Net Income (Loss) Per Share Attributable to Common Shareholders | 19. Net Income (Loss) Per Share Attributable to Common Shareholders The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except share and per share data):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Numerator : |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) attributable to common shareholders – Basic |  | $ | 28,944 |  |  | $ | (10,295 | ) |  | $ | (14,163 | ) |  | $ | (20,055 | )
Less interest expense on potentially dilutive convertible notes payable |  | $ | 196 |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Net income (loss) attributable to common shareholders - Diluted |  | $ | 29,140 |  |  | $ | (10,295 | ) |  | $ | (14,163 | ) |  | $ | (20,055 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding –Basic |  |  | 62,071,754 |  |  |  | 17,358,159 |  |  |  | 61,307,699 |  |  |  | 17,358,159 |
Weighted average effect of potentially dilutive securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Effect of potentially dilutive stock options |  |  | 5,791,023 |  |  |  | - |  |  |  | - |  |  |  | - |
Effect of potentially dilutive common stock warrants |  |  | 1,485,049 |  |  |  | - |  |  |  | - |  |  |  | - |
Effect of potentially dilutive convertible notes payable |  |  | 482,703 |  |  |  | - |  |  |  | - |  |  |  | - |
Effect of potentially dilutive restricted stock awards |  |  | 208,105 |  |  |  | - |  |  |  | - |  |  |  | - |
Weighted average common shares outstanding –Diluted |  |  | 70,038,634 |  |  |  | 17,358,159 |  |  |  | 61,307,699 |  |  |  | 17,358,159 |
Net income (loss) per share attributable to common shareholders: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.47 |  |  | $ | (0.59 | ) |  | $ | (0.23 | ) |  | $ | (1.16 | )
Diluted |  | $ | 0.42 |  |  | $ | (0.59 | ) |  | $ | (0.23 | ) |  | $ | (1.16 | )
Included within weighted average common shares outstanding are the remaining 117,500 (originally 1,119,750) common shares issuable upon the exercise of the December 2020 PIPE Warrants, as these warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common shareholders. The following shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per share attributable to common shareholders for the periods presented because including them would have been antidilutive, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period, or they were out-of-the money:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Series D redeemable convertible preferred stock |  |  | - |  |  |  | 9,394,057 |  |  |  | - |  |  |  | 9,394,057 |
Series C redeemable convertible preferred stock |  |  | - |  |  |  | 7,264,519 |  |  |  | - |  |  |  | 7,264,519 |
Series B redeemable convertible preferred stock |  |  | - |  |  |  | 4,168,815 |  |  |  | - |  |  |  | 4,168,815 |
Series A redeemable convertible preferred stock |  |  | - |  |  |  | 16,066,503 |  |  |  | - |  |  |  | 16,066,503 |
Series D redeemable convertible preferred stock warrants |  |  | - |  |  |  | 320,441 |  |  |  | - |  |  |  | 320,441 |
Series A redeemable convertible preferred stock warrants |  |  | - |  |  |  | 1,608,670 |  |  |  | - |  |  |  | 1,608,670 |
Convertible notes payable (see Note 11) |  |  | - |  |  |  | - |  |  |  | 482,703 |  |  |  | - |
Common stock warrants (see Note 10) |  |  | 2,523,351 |  |  |  | - |  |  |  | 4,569,962 |  |  |  | - |
Options to purchase common stock |  |  | 2,685,575 |  |  |  | 7,509,810 |  |  |  | 9,063,423 |  |  |  | 7,509,810 |
Restricted stock awards |  |  | 1,100,050 |  |  |  | - |  |  |  | 1,245,489 |  |  |  | - |
Chardan Unit Purchase Option Warrants (see Notes 3 and 10) |  |  | 24,583 |  |  |  | - |  |  |  | 24,583 |  |  |  | - |
Clene Nanomedicine contingent earn-out shares (see Note 3 and 12) |  |  | 8,346,185 |  |  |  | - |  |  |  | 8,346,185 |  |  |  | - |
Initial Shareholders contingent earn-out shares (see Note 3 and 12) |  |  | 750,000 |  |  |  | - |  |  |  | 750,000 |  |  |  | - |
Total |  |  | 15,429,744 |  |  |  | 46,332,815 |  |  |  | 24,482,345 |  |  |  | 46,332,815 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration